Anti-Spike SARS-CoV-2 IgG Assessment with a Commercial Assay during a 4-Month Course after COVID-19 Vaccination
We intended to assess the humoral response induced by the Pfizer/BioNTech Comirnaty COVID-19 vaccine with commercially available immunoassays: anti-spike (S) IgG and IgM, and anti-nucleocapsid (N) IgG antibodies, over a 4-month course. One hundred subjects, including 15 COVID-19 convalescents, compr...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-11-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/9/11/1367 |
| _version_ | 1797508265512271872 |
|---|---|
| author | Jakub Swadźba Tomasz Anyszek Andrzej Panek Emilia Martin |
| author_facet | Jakub Swadźba Tomasz Anyszek Andrzej Panek Emilia Martin |
| author_sort | Jakub Swadźba |
| collection | DOAJ |
| description | We intended to assess the humoral response induced by the Pfizer/BioNTech Comirnaty COVID-19 vaccine with commercially available immunoassays: anti-spike (S) IgG and IgM, and anti-nucleocapsid (N) IgG antibodies, over a 4-month course. One hundred subjects, including 15 COVID-19 convalescents, comprised the study cohort. The SARS-CoV-2 antibodies concentrations were measured on day 0′ and 10′, 20′, 30′, 60′, 90′, and 120′ after the first dose administration. Over the course of the study, 100% of the participants developed and sustained anti-SARS-CoV-2 S IgG antibodies. The highest concentration, exceeding the quantification range of the test (2080 BAU/mL), was reached by 67% of the subjects on day 30′. The concentration of the antibodies remained stable between days 30′ and 90′ but was followed by a significant decrease between days 90′ and 120′. The stronger and more persistent humoral response was noted for women. The COVID-19 convalescents developed higher antibody levels, particularly 10 days after the first Comirnaty dose. Twenty-three out of the eighty-five naïve vaccinees failed to develop a detectable IgM response. LIAISON<sup>®</sup> SARS-CoV-2 TrimericS IgG (DiaSorin S.p.A, Saluggia, Italy) may be useful in the assessment of the humoral response to the Comirnaty vaccine. In contrast, Abbott’s anti-S SARS-CoV-2 IgM has a limited utility in this context. |
| first_indexed | 2024-03-10T05:00:16Z |
| format | Article |
| id | doaj.art-81d9d99ff95c4f208db17f815b29de2e |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-10T05:00:16Z |
| publishDate | 2021-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-81d9d99ff95c4f208db17f815b29de2e2023-11-23T01:53:53ZengMDPI AGVaccines2076-393X2021-11-01911136710.3390/vaccines9111367Anti-Spike SARS-CoV-2 IgG Assessment with a Commercial Assay during a 4-Month Course after COVID-19 VaccinationJakub Swadźba0Tomasz Anyszek1Andrzej Panek2Emilia Martin3Department of Laboratory Medicine, Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski Krakow University, 30-705 Krakow, PolandDepartment of Laboratory Medicine, Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski Krakow University, 30-705 Krakow, PolandMedical Department Diagnostyka S.A., 31-864 Krakow, PolandMedical Department Diagnostyka S.A., 31-864 Krakow, PolandWe intended to assess the humoral response induced by the Pfizer/BioNTech Comirnaty COVID-19 vaccine with commercially available immunoassays: anti-spike (S) IgG and IgM, and anti-nucleocapsid (N) IgG antibodies, over a 4-month course. One hundred subjects, including 15 COVID-19 convalescents, comprised the study cohort. The SARS-CoV-2 antibodies concentrations were measured on day 0′ and 10′, 20′, 30′, 60′, 90′, and 120′ after the first dose administration. Over the course of the study, 100% of the participants developed and sustained anti-SARS-CoV-2 S IgG antibodies. The highest concentration, exceeding the quantification range of the test (2080 BAU/mL), was reached by 67% of the subjects on day 30′. The concentration of the antibodies remained stable between days 30′ and 90′ but was followed by a significant decrease between days 90′ and 120′. The stronger and more persistent humoral response was noted for women. The COVID-19 convalescents developed higher antibody levels, particularly 10 days after the first Comirnaty dose. Twenty-three out of the eighty-five naïve vaccinees failed to develop a detectable IgM response. LIAISON<sup>®</sup> SARS-CoV-2 TrimericS IgG (DiaSorin S.p.A, Saluggia, Italy) may be useful in the assessment of the humoral response to the Comirnaty vaccine. In contrast, Abbott’s anti-S SARS-CoV-2 IgM has a limited utility in this context.https://www.mdpi.com/2076-393X/9/11/1367SARS-CoV-2 antibodiesCOVID-19 testingCOVID-19 vaccinesCOVID-19 vaccines booster shot |
| spellingShingle | Jakub Swadźba Tomasz Anyszek Andrzej Panek Emilia Martin Anti-Spike SARS-CoV-2 IgG Assessment with a Commercial Assay during a 4-Month Course after COVID-19 Vaccination Vaccines SARS-CoV-2 antibodies COVID-19 testing COVID-19 vaccines COVID-19 vaccines booster shot |
| title | Anti-Spike SARS-CoV-2 IgG Assessment with a Commercial Assay during a 4-Month Course after COVID-19 Vaccination |
| title_full | Anti-Spike SARS-CoV-2 IgG Assessment with a Commercial Assay during a 4-Month Course after COVID-19 Vaccination |
| title_fullStr | Anti-Spike SARS-CoV-2 IgG Assessment with a Commercial Assay during a 4-Month Course after COVID-19 Vaccination |
| title_full_unstemmed | Anti-Spike SARS-CoV-2 IgG Assessment with a Commercial Assay during a 4-Month Course after COVID-19 Vaccination |
| title_short | Anti-Spike SARS-CoV-2 IgG Assessment with a Commercial Assay during a 4-Month Course after COVID-19 Vaccination |
| title_sort | anti spike sars cov 2 igg assessment with a commercial assay during a 4 month course after covid 19 vaccination |
| topic | SARS-CoV-2 antibodies COVID-19 testing COVID-19 vaccines COVID-19 vaccines booster shot |
| url | https://www.mdpi.com/2076-393X/9/11/1367 |
| work_keys_str_mv | AT jakubswadzba antispikesarscov2iggassessmentwithacommercialassayduringa4monthcourseaftercovid19vaccination AT tomaszanyszek antispikesarscov2iggassessmentwithacommercialassayduringa4monthcourseaftercovid19vaccination AT andrzejpanek antispikesarscov2iggassessmentwithacommercialassayduringa4monthcourseaftercovid19vaccination AT emiliamartin antispikesarscov2iggassessmentwithacommercialassayduringa4monthcourseaftercovid19vaccination |